Article
A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon.
PloS one - 1 Jan 2014
Pancoska Petr, Kirkwood John M, Bouros Spyros, Spyropoulou-Vlachou Maria, Pectasides Eirini, Tsoutsos Dimosthenis, Polyzos Aristidis, Markopoulos Christos, Panagiotou Petros, Castana Ourania, Bafaloukos Dimitrios, Fountzilas George, Gogas Helen
Abstract excerpt
Adjuvant therapy of stage IIB/III melanoma with interferon reduces relapse and mortality by up to 33% but is accompanied by toxicity-related complications. Polymorphisms of the CTLA-4 gene associated with autoimmune diseases could help in identifying interferon treatment benefits. We previously g...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.